No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer By Ogkologos - August 19, 2025 432 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTER 70s study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment MOST POPULAR Selumetinib Continues to Show Promise in Children with NF1 June 8, 2018 Cuando necesita ayuda con responsabilidades de cuidado June 15, 2021 Finding Hope in the New Year During COVID-19 and Cancer January 6, 2021 Survivor Sees Mom Fighting Breast Cancer At Brunch And Pays For... December 2, 2019 Load more HOT NEWS Working towards equal cancer care for everyone Metformin May Affect Risk of Breast Cancer in Women with Type... EMA Recommends Extension of Therapeutic Indications for Irinotecan Hydrochloride Trihydrate Staging at Presentation for Patients with Localised Pancreatic Ductal Adenocarcinoma Should...
